A monoclonal antibody treatment for Alzheimer's disease that showed promise in a Phase 3 trial may have contributed to a study participant's death, according to an adverse events report obtained by the digital health publication Stat.Eisai, the company that makes the experimental drug lecanemab, said in a statement to CNN on Friday that because of patient privacy issues, it could not provide specific information about patients or comment on information from other sources.
#information #united-states #participants #heart-attack #clinical-trials #participant #side-effect #heart-condition
[
add
]
[
|
|
...
]